文献速递生殖医学

胚胎植入前非整倍体遗传学检测具有成本效益、缩短治疗时间并降低胚胎移植失败和临床流产风险

Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage.
PubMed 文献 · Fertil Steril · 2018-01-01

该决策分析模型比较体外受精(IVF)联合或不联合胚胎植入前非整倍体遗传学检测(PGT-A)的成本与临床结局,纳入74个IVF中心的8998例≤42岁女性。对于胚胎数>1的患者,PGT-A组成本差为931–2411美元(依筛查胚胎数而定),累计活产率两组相当,但PGT-A缩短治疗时间最多4个月,并减少移植失败和临床流产。

要点

  • 胚胎数>1时,PGT-A可降低IVF相关成本,成本差为931–2411美元。
  • PGT-A缩短治疗时间最多4个月,累计活产率两组相当。
  • PGT-A组移植失败和临床流产更少。

核心结论

  • 对于胚胎数>1的患者,与单纯IVF相比,IVF联合PGT-A可降低医疗成本、缩短治疗时间并降低胚胎移植失败和临床流产风险。

研究设计与样本

  • 决策分析模型,比较IVF联合或不联合PGT-A两种策略的成本与临床结局,纳入来自74个IVF中心的8998例≤42岁接受IVF的女性。

主要发现

  • 对于胚胎数>1的患者,成本差倾向于使用PGT-A,范围为931–2411美元,取决于筛查的胚胎数。
  • 当所有胚胎用尽后,两组累计活产率相当。
  • PGT-A使治疗时间缩短最多4个月。
  • 接受PGT-A的患者经历更少的胚胎移植失败和临床流产。

临床怎么用

  • 作者结论认为,对于胚胎数>1的患者,IVF联合PGT-A可降低医疗成本、缩短治疗时间并降低胚胎移植失败和临床流产风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if preimplantation genetic testing for aneuploidy (PGT-A) is cost-effective for patients undergoing in vitro fertilization (IVF). DESIGN: Decision analytic model comparing costs and clinical outcomes of two strategies: IVF with and without PGT-A. SETTING: Genetics laboratory. PATIENTS: Women ≤ 42 years of age undergoing IVF. INTERVENTION(S): Decision analytic model applied to the above patient population utilizing a combination of actual clinical data and assumptions from the literature regarding the outcomes of IVF with and without PGT-A. MAIN OUTCOME MEASURE(S): The primary outcome was cumulative IVF-related costs to achieve a live birth or exhaust the embryo cohort from a single oocyte retrieval. The secondary outcomes were time from retrieval to the embryo transfer resulting in live birth or completion of treatment, cumulative live birth rate, failed embryo transfers, and clinical losses. RESULTS: 8,998 patients from 74 IVF centers were included. For patients with greater than one embryo, the cost differential favored the use of PGT-A, ranging from $931-2411 and depending upon number of embryos screened. As expected, the cumulative live birth rate was equivalent for both groups once all embryos were exhausted. However, PGT-A reduced time in treatment by up to four months. In addition, patients undergoing PGT-A experienced fewer failed embryo transfers and clinical miscarriages. CONCLUSION: For patients with > 1 embryo, IVF with PGT-A reduces healthcare costs, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage when compared to IVF alone.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Neal SA, Morin SJ, Franasiak JM, et al. Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage. Fertil Steril. 2018. PMID: 30316435. doi:10.1016/j.fertnstert.2018.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。